Pharmacodynamic and Pharmacokinetic Dose Ranging Study of Tiotropium Bromide Administered Via Inhalation Solution in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Completed · Phase 2 · Has a placebo group
Conditions studied: Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD)
In brief
Pharmacodynamic and Pharmacokinetic Dose Ranging Study of Tiotropium Bromide Administered Via Inhalation Solution in Patients With Chronic Obstructive Pulmonary Disease (COPD).
Key facts
- Study ID
- NCT03118765
- Run by
- Glenmark Specialty S.A.
- People needed
- 155
- Starts
- 2017-03-24
- Expected to finish
- 2017-07-31
- Last updated by the study team
- 2019-08-01
Who can join
Age: 40 and older, up to 85. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Male and female subjects ≥40 years and ≤85 years of age at the time of consent.
- Subject must have a primary diagnosis of mild or moderate COPD defined as post-bronchodilator FEV1/FVC ratio of <70% and FEV1 of ≥50% of predicted normal value as per the NHANES III predicted normal values at screening.
- Willing to stop all other COPD medications or other medications which will interfere with the study results for the entire duration of the study, except albuterol/salbutamol as needed.
- Current or ex-smoker with ≥10 pack-year smoking history.
You may not qualify if…
- Subjects with a chest x-ray/CT scan that suggests a diagnosis other than COPD (eg, pneumonia, other infection, atelectasis, or pneumothorax or other active/ongoing pulmonary conditions) and taken within 6 months prior to study start. If there is no chest x-ray or CT scan taken within 6 months prior to study start, or if recent results are unavailable for review, a chest x-ray must be performed.
- Use of oral/parenteral corticosteroids or antibiotics for COPD within 6 weeks or depot corticosteroids within 3 months prior to screening or subject has had a change in dose or type of any medications for COPD within 14 days before screening.
- Hospitalization for COPD exacerbation or pneumonia within 3 months prior to screening.
- Subjects with a history of asthma, with the exception of outgrown childhood asthma, defined as transient wheezers outgrown by 5 years of age.
- Subject has a known history of alpha 1 antitrypsin deficiency-related emphysema.
- Subject requires nocturnal oxygen or continuous supplemental oxygen therapy.
- Subject with history of a positive result for HBsAg or HCV antibody.
- Subject is known to be seropositive for human immunodeficiency virus.
- Female subject is pregnant or lactating.
- Subject has a history of allergic reaction to the anti-cholinergic or any components of the study medications.
Where it is running
- Glenmark Investigational Site 23 — Andalusia, Alabama, United States
- Glenmark Investigational Site 12 — Phoenix, Arizona, United States
- Glenmark Investigational Site 14 — Tempe, Arizona, United States
- Glenmark Investigational Site 17 — Fullerton, California, United States
- Glenmark Investigational Site 19 — Edgewater, Florida, United States
- Glenmark Investigational Site 24 — Miami, Florida, United States
- Glenmark Investigational Site 16 — Miami, Florida, United States
- Glenmark Investigational Site 10 — Miami Lakes, Florida, United States
- Glenmark Investigational Site 6 — Orlando, Florida, United States
- Glenmark Investigational Site 20 — Ormond Beach, Florida, United States
- Glenmark Investigational Site 21 — Vero Beach, Florida, United States
- Glenmark Investigational Site 13 — Winter Park, Florida, United States
- Glenmark Investigational Site 18 — Las Vegas, Nevada, United States
- Glenmark Investigational Site 9 — Charlotte, North Carolina, United States
- Glenmark Investigational Site 5 — Columbus, Ohio, United States
- Glenmark Investigational Site 22 — Columbus, Ohio, United States
- Glenmark Investigational Site 8 — Dublin, Ohio, United States
- Glenmark Investigational Site 11 — Medford, Oregon, United States
- Glenmark Investigational Site 3 — Easley, South Carolina, United States
- Glenmark Investigational Site 2 — Greenville, South Carolina, United States
- Glenmark Investigational Site 4 — Greenville, South Carolina, United States
- Glenmark Investigational Site 1 — Rock Hill, South Carolina, United States
- Glenmark Investigational Site 15 — Spartanburg, South Carolina, United States
- Glenmark Investigational Site 7 — Spartanburg, South Carolina, United States
- Glenmark Investigational Site 25 — Tomball, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.